Batten Disease Treatment Market Size, Share, Trends, Growth and Forecast 2032

The global Batten Disease Treatment Market size was worth around USD 40.2 Million in 2023 and is predicted to grow to around USD 65.2 Million by 2032 with a compound annual growth rate (CAGR) of roughly 5.50% between 2024 and 2032.

Request Free Sample

The report covers forecast and analysis for the batten disease treatment market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2023 to 2032 based revenue (USD Million) the study includes drivers and restraints for the batten disease treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the batten disease treatment market on a global level.

Batten Disease Treatment Market: Overview

Batten disease is a rare, inherent, and fatal nervous system disorder. It is the most general form of a group of disorders named the neuronal ceroid lipofuscinoses (NCLs), which is known to be a class of life-limiting neurogenerative genetic diseases that are triggered because of abnormality of genes resulting in their inability to synthesize the essential protein.

Batten disease is also known as Neuronal Ceroid Lipofuscinoses (NCL), which is a very rare, fatal, life-threatening autosomal, genetically inherited disorder. This disorder is caused due to the abnormality of genes which are required to synthesize the required protein. This affects children and mostly observed in juvenile phase due to the mutation of CLN3 gene. This disorder leads to genetic mutations which result in neurological impairment, loss of motor skills, seizures, loss of ability to communicate and walk visual impairments and others. In this disorder, genetic mutations interrupt the ability of cells to dispose of the wastes. This disease can be diagnosed with the help of different medical examinations which include blood and urine test, MRI, DNA analysis, electroencephalogram, and skin or tissue sampling. This disease, fall under the category of lysosome storage disorder.

Batten disease treatment market is driven by the increased prevalence of Batten disease and it led to increases in patient educations programs to increase awareness among people. National Institutes are taking up the initiative in R&D for the development of batten disease cure. There is an increase in healthcare infrastructure and expenditure results in the increase of batten disease treatment market. There is no effective cure for this disease, few drugs and vitamins are available which reduces the symptoms and companies are involved in the discovery of effective drug.

Recently in 2017, FDA has approved Brineura (Cerliponase Alfa) for the treatment of Batten disease. This drug slows downs the loss of walking ability. There are ongoing clinical trials for the various drug that can be used for the treatment include rhTPP 1 (BMN 190)and other drugs. There is no established cure or prevention for this disease and symptoms of this disease take a long time to be noticed are the factors expected to affect the growth of batten disease treatment market.

In order to give the users of this report a comprehensive view on the batten disease treatment market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis. Wherein test type segments and therapy segments are benchmarked based on their market size, growth, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the players in the market. In addition, the report also covers key strategic developments of the market including acquisitions and mergers, new technology launch, agreements, partnerships collaborations& joint ventures, research & development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, disease portfolio of various companies according to the region.

Request Free Sample

Global Batten Disease Treatment Market: Segmentation

The study provides a decisive view on the batten disease treatment market by segmenting the market based on disease type and therapy type and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on disease market is segmented into Infantile NCL, Late Infantile NCL, Juvenile NCL, and Adult NCL.

Based therapy type covered in this report includes occupational and physical therapies.

Batten Disease Treatment Market: Report Scope

Batten Disease Treatment Market: Regional Analysis

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries including the U.S., Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for Batten disease treatment market based on disease type and therapies in all the regions and countries.

North America is expected to dominate the batten disease treatment market closely followed by Europe over the forecast period. Due to the increased prevalence of Batten disease in these regions and increase in clinical trials, and increased awareness in these regions are expected to support the growth of the market. Asia Pacific market is expected to grow moderately due to lack of awareness among people and manufacturers. Latin America and Middle East Africa are expected to grow considerably over the forecast period.

Some of the major players operating in the Batten Disease Treatment Market are:

• Novartis AG (Switzerland)
• Abeona Therapeutics Inc. (U.S.)
• Alexion Pharmaceuticals Inc. (U.S.)
• Amicus Therapeutics (U.S.)
• Lysogene (France)
• Biogen (U.S.)
• BioMarin Pharmaceutical Inc. (U.S.)
• Denali Therapeutics (U.S.)
• Dimension Therapeutics, Inc. (U.S.)
• Edison Pharmaceuticals (U.S.)
• GeneTx Biotherapeutics LLC (U.S.)
• Orchard Therapeutics (U.K.)
• Passage Bio (U.S.)
• Teva Pharmaceuticals Industries Ltd. (Ireland)
• Zydus Cadila (India)
• Mylan (U.S.)
• Regenxbio Inc. (U.S.)

This report segments the global batten disease treatment market as follows: 

Global Batten Disease Treatment Market: Disease Type Segment Analysis

• Infantile NCL
• Late Infantile NCL
• Juvenile NCL
• Adult NCL

Global Batten Disease Treatment Market: Therapy type Segment Analysis

• Occupational Therapy 
• Physical Therapy

Global Batten Disease Treatment Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa